Financial News

Financial Report: AbbVie

HUMIRA sales up 17% in the quarter

AbbVie

2Q Revenues:$6.5 billion (+18%)

2Q Earnings: $1.6 billion (+18%)

YTD Revenues: $12.4 billion (+18%)

YTD Earnings: $3.0 billion (+24%)

Comments: HUMIRA sales increased 17% to $4.1 billion in the quarter. IMBRUVICA revenue reached $439 million in the quarter and Viekira sales were $419 million, up 9%. Lupron sales were $219 million, up 10%. Synthroid sales were $188 million, up 1% and Creon sales were $180 million, up 13%. Kaletra sales fell 12% to $146 million. In the quarter, the company received regulatory approvals for VENCLEXTA and ZINBRYTA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters